Neurocrine Biosciences, Inc.
$130.77
▲
0.42%
2026-04-22 10:12:13
www.neurocrine.com
NMS: NBIX
Explore Neurocrine Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$13.18 B
Current Price
$130.77
52W High / Low
$160.18 / $98.95
Stock P/E
28.05
Book Value
$32.5
Dividend Yield
—
ROCE
16.37%
ROE
16.38%
Face Value
—
EPS
$4.67
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,000
Beta
0.35
Debt / Equity
14.49
Current Ratio
3.39
Quick Ratio
3.3
Forward P/E
15.07
Price / Sales
4.52
Enterprise Value
$11.93 B
EV / EBITDA
17.89
EV / Revenue
4.17
Rating
Strong Buy
Target Price
$184.73
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Alkermes plc | $34.23 | 23.69 | $5.73 B | — | 13.07% | 14.72% | $36.48 / $25.16 | $10.99 |
| 2. | Sunshine Biopharma, Inc. | $1.02 | — | $5.05 M | — | -23.97% | -25.68% | $2.43 / $0.95 | $5.31 |
| 3. | Indivior Pharmaceuticals, Inc. | $32.42 | 31.62 | $3.95 B | — | 92.33% | -96.33% | $38 / $8.69 | $-0.78 |
| 4. | PRF Technologies Ltd. | $2.64 | — | $2.31 M | — | -53.59% | -90.37% | $17.95 / $1.8 | $10.29 |
| 5. | Biofrontera Inc. | $1.09 | — | $12.81 M | — | -68.08% | -1.41% | $1.19 / $0.54 | $0.9 |
| 6. | Organogenesis Holdings Inc. | $2.52 | 8.75 | $324.17 M | — | 11.21% | 9.04% | $7.08 / $2.21 | $2.36 |
| 7. | Viatris Inc. | $14.78 | — | $17.2 B | 3.23% | 0.84% | -21.08% | $16.47 / $7.39 | $12.78 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 805.5 M | 794.9 M | 687.5 M | 572.6 M | 627.7 M | — |
| Operating Profit | 227.9 M | 239.3 M | 145.6 M | 23.7 M | 145 M | — |
| Net Profit | 153.7 M | 209.5 M | 107.5 M | 7.9 M | 103.1 M | — |
| EPS in Rs | 1.53 | 2.09 | 1.07 | 0.08 | 1.03 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.86 B | 2.36 B | 1.89 B | 1.49 B |
| Operating Profit | 636.5 M | 583 M | 394.8 M | 249 M |
| Net Profit | 478.6 M | 341.3 M | 249.7 M | 154.5 M |
| EPS in Rs | 4.77 | 3.4 | 2.49 | 1.54 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 4.63 B | 3.72 B | 3.25 B | 2.37 B |
| Total Liabilities | 1.38 B | 1.13 B | 1.02 B | 660.9 M |
| Equity | 3.25 B | 2.59 B | 2.23 B | 1.71 B |
| Current Assets | 2.52 B | 1.72 B | 1.61 B | 1.45 B |
| Current Liabilities | 743.4 M | 507.7 M | 654.8 M | 537.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 782.7 M | 595.4 M | 389.9 M | 339.4 M |
| Investing CF | -264.4 M | -126.8 M | -467.1 M | -177.1 M |
| Financing CF | -38.3 M | -486.7 M | 65.3 M | -234.3 M |
| Free CF | 748.7 M | 557.2 M | 361.6 M | 322.9 M |
| Capex | -34 M | -38.2 M | -28.3 M | -16.5 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 24.81% | 26.76% | — | — |
| Earnings Growth % | 36.68% | 61.62% | — | — |
| Profit Margin % | 14.49% | 13.23% | 10.38% | — |
| Operating Margin % | 24.75% | 20.92% | 16.73% | — |
| Gross Margin % | 98.56% | 97.9% | 98.44% | — |
| EBITDA Margin % | 27.16% | 22.05% | 17.77% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.